PET Imaging Evaluation of [11C]SY08

Recruiting now · Early Phase 1

Conditions studied: Parkinson's Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Healthy Controls

In brief

The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are: 1. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in healthy individuals. 2. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in patients with alpha synuclein aggregates in the brain, including PD, DLB and MSA. 3. To determine human dosimetry of \[11C\]SY08 in healthy individuals An intravenous bolus injection of \[11C\]SY08 will be administered per subject for brain PET imaging.

Key facts

Study ID: NCT06098612
Run by: Massachusetts General Hospital
People needed: 40
Starts: 2024-05-01
Expected to finish: 2027-11-01
Last updated by the study team: 2025-12-24

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

General Inclusion criteria, all subjects must:
Age 50-80
Be able to provide written informed consent or assent
Be able to read, speak and understand English (The investigators do not have the resources necessary to properly study non-English speaking patients in this study, given that translation and validation of the assessment tools would be necessary)
Be willing and able to participate in one PET/MRI scanning session
Additional Inclusion criteria for PD patients, subjects must:
Have an existing diagnosis of idiopathic PD, using consensus criteria
Stable medications for at least 30 days
Hoehn and Yahr stage I-IV
A study partner who can answer questions pertaining to daily functioning
Additional Inclusion criteria for MSA patients, subjects must:
Have an existing diagnosis of MSA, using consensus criteria
Stable medications for at least 30 days
MSAp or MSAc
A study partner who can answer questions pertaining to daily functioning
Additional Inclusion criteria for DLB patients, subjects must:
Have an existing diagnosis of probable DLB, using consensus criteria
Stable medications for at least 30 days
Clinical Dementia Rating Scale (CDR) < 0.5
A study partner who can answer questions pertaining to daily functioning

You may not qualify if…

General Exclusion Criteria (All Subjects)
History of vascular risk factors (e.g. hypertension, hyperlipidemia), if not well-controlled
Major psychiatric disease (e.g.schizophrenia)
History of stroke
Focal brain lesions on MRI scans
History of other major illnesses including, but not limited to, major kidney or liver problems or significant neurological illness
Recent surgery that is deemed major by our reviewing physician or nurse practitioner within the past 6 months
History of head trauma (as defined as having any insults to the brain that may have resulted from an external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile)
Impaired elimination (as defined as having problems with urination) unless being managed
Past or present diagnosis of bipolar disorder or other Axis I diagnosis, (treated depression is allowed)
Any present substance abuse including drug/alcohol abuse
Inability to lie flat on camera bed for up to 90 min
Pregnancy or breastfeeding
Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan
Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits (50 milliSieverts)
General MR and PET safety exclusion criteria listed below
Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, steel implants, ferromagnetic objects such as jewelry or metal clips in clothing
Electrical implants such as cardiac pacemakers or perfusion pumps
Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
Is unable to lie comfortably on a bed inside a PET camera with their head in the field of view for 60 to 90 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis)
Pregnancy: A negative serum pregnancy test is required on the day of the PET procedure in women of child bearing potential
Body weight of > 300 lbs (weight limit of the MRI table)
Breast feeding mothers
Exclusion Criteria for Subjects Undergoing Blood Draws Through an Arterial Line During PET Scan
An abnormal result on the modified Allen's test on both hands

Where it is running

MGH — Charlestown, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.